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Complement is a key arm of the innate immune defenses against the pathogenic neisseriae. We previously
identified lipooligosaccharide on Neisseria meningitidis as an acceptor for complement C4b. Little is known
about other neisserial targets for complement proteins C3 and C4, which covalently attach to bacterial surfaces
and initiate opsonization and killing. In this study we demonstrate that Neisseria gonorrhoeae porin (Por) 1B
selectively binds C4b via amide linkages and C3b via ester linkages. Using strains expressing hybrid Por1A/1B
molecules, a region spanned by loops 4 and 5 of Por1B was identified as the preferred binding site for C4b. We
also identified the opacity protein (Opa), a major adhesin of pathogenic neisseriae, as a target for C4b and C3b
on both N. meningitidis and N. gonorrhoeae. Using N. gonorrhoeae variants that predominantly expressed
individual Opa proteins, we found that all Opa proteins tested (A, B, C, D, E, F, and I) bound C4b and C3b
via amide and ester linkages, respectively. Amide linkages with Por1B and Opa were confirmed using serum
containing only the C4A isoform, which exclusively forms amide linkages with targets. While monomers and
heterodimers of C4Ab were detected on bacterial targets, C4Bb appeared to preferentially participate in
heterodimer (C5 convertase) formation. Our data provide another explanation for the enhanced serum
sensitivity of Por1B-bearing gonococci. The binding of C3b and C4b to Opa provides a rationale for the
recovery of predominantly “transparent” (Opa-negative) neisserial isolates from persons with invasive disease,
where the bacteria encounter high levels of complement.
Complement is an important arm of the innate immune
system that combats neisserial infections. Persons deficient in
terminal complement components are predisposed to recur-
rent neisserial infections (19, 60). The complement cascade
comprises the classical, lectin, and alternative pathways. All
three pathways converge at the level of C3b deposition. C3b is
an integral component of both the classical and alternative
pathway C5 convertases (C4bC3b,C2a and C3bC3b,Bb, respec-
tively), which cleave C5 to initiate membrane attack complex
(C5b-9) formation. Prior work has shown that antibody (Ab)-
dependent classical pathway activation is essential to initiate
direct complement-dependent neisserial killing (31). Binding
of complement-fixing immunoglobulin to the bacterial surface
results in binding of the activated C1 complex to appropriately
spaced Fc domains. Activated C1s in the complex first cleaves
C4 to C4b, which covalently binds, either via an ester or an
amide linkage, to the bacterial surface and then cleaves C2 that
binds to C4b, leading to the formation of the C4b,C2a com-
plex, which is the C3 convertase of the classical pathway. Bind-
ing of a C3b molecule to or close to the classical pathway C3
convertase imparts C5 convertase activity to the enzyme com-
plex (reviewed in reference 75). Similarly, C3b covalently
bound to the bacterium can bind factor B to form the C3bB
complex. Cleavage of factor B in this complex by the enzyme
factor D leads to formation of the alternative pathway C3
convertase, which can further cleave more C3 molecules to
C3b. Binding of a second C3b molecule to the C3 convertase
results in C5 convertase activity by forming C3bC3b,Bb.
The early events in complement activation, in particular,
targets for C4b and C3b, on neisseriae have not been well
defined. Edwards et al. have shown that gonococcal lipooligo-
saccharide (LOS) serves as a site for C3 deposition (15), and
we have shown that meningococcal LOS is a target for C4b and
that the location of phosphoethanolamine residues on heptose
II determines the nature of the C4b linkage and modulates
serum resistance of bacteria (49). In this study we characterize
additional ligands for C4b and C3b on Neisseria gonorrhoeae
and Neisseria meningitidis. This investigation provides a better
understanding of how complement is activated on the neisse-
rial surface and provides further insights into the pathogenesis
of these organisms.
MATERIALS AND METHODS
Bacterial strains. Neisserial strains were routinely cultured on chocolate agar
plates supplemented with IsoVitaleX equivalent at 37°C in an atmosphere of 5%
carbon dioxide. N. gonorrhoeae strains MS11 (41), F62 (63), FA1090 (76) (all
Por1B), and UU1 (77), 15253 (78), and FA19 (46) (all Por1A) have been
described previously. Opa phase variants of strain FA1090 that express predom-
inately a single Opa protein (A, B, C, D, E, or F), an Opa-negative strain
(FA1090 OpaA-K), in which all opa genes have been genetically inactivated, and
an OpaI-expressing strain and an OpaB phase-locked strain (the latter two
strains were constructed in the FA1090 OpaA-K background) were all provided
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by Janne Cannon (University of North Carolina, Chapel Hill). Methods for the
selection of specific Opa phase variants have been described previously and were
used to independently validate the Opa expression of these strains (35). Gono-
coccal strains bearing FA19/MS11 hybrid Por molecules (9) were provided by
P. F. Sparling and C. Elkins (both of the University of North Carolina, Chapel
Hill).
N. meningitidis strains MC58 (72) and H44/76 (25) have been described pre-
viously. MC58 siaD lst was constructed by insertional inactivation of both the
polysialyltransferase (siaD) gene and the LOS sialyltransferase (lst) gene as
described previously (39, 49). These mutations resulted in the loss of expression
of capsular polysaccharide and in the inability to sialylate LOS. Serogroup A
meningococcal strain Z2087 (24) and its Opa-negative isogenic mutant were also
provided by Janne Cannon.
Sera and complement reagents. Normal human serum (NHS), isolated from
seven healthy human volunteers with no prior history of immunization with the
meningococcal vaccine, was pooled and stored at 80°C. NHS contains two
isoforms of C4 called C4A and C4B. Serum containing only C4A or C4B (C4B
and C4A deficient, respectively) has been previously described (64) and was
provided by Seppo Meri (Haartman Institute, Helsinki, Finland). These sera
were obtained from individuals without known deficiencies of other complement
components.
Antibodies. Polyclonal sheep anti-human C4 (Biodesign, Saco, ME) was used
in Western blotting experiments as described previously (49). To selectively
detect C3b bound to bacteria in Western blot assays, monoclonal Ab (MAb) 755,
which is directed against the C-terminal end (amino acids 1499 to 1519 of C3) of
the -chain of C3, was used (37, 74). Similarly, iC3b-target complexes were
localized using MAb G-3E (30). Anti-Por1B MAb 5.51 is specific for the fifth
loop of MS11 Por1B (17), and anti-Opa MAb 4B12 recognizes nearly all neis-
serial Opa proteins.
To produce polyclonal anti-Opa antibody, Opa was purified from N. menin-
gitidis MC58 as previously described (4) and five female, 6- to 8-week-old
C57B/6J mice (Jackson Laboratories, Bar Harbor, ME) were each immunized
subcutaneously with 50 g of purified Opa emulsified in complete Freund’s
adjuvant. Mice were given booster injections at week 4. Antisera were collected
at weeks 4 and 7 by tail bleed. Anti-Opa antibodies were measured by enzyme-
linked immunosorbent assay, and specificity of the sera was assessed by Western
blotting against whole-cell lysates (see Fig. S1 in the supplemental material).
Detection of C4b and C3b targets. Western blotting to localize C4- and C3-
target complexes was carried out as described previously (49). Briefly, 3  108
bacteria suspended in Hanks balanced salt solution (HBSS) containing 0.15 mM
CaCl2 and 1 mM MgCl2 (HBSS2) were incubated with NHS (concentration
specified for each experiment) in a final reaction volume of 500 l for 30 min at
37°C. Bacteria were washed twice in HBSS2 and divided into two aliquots that
were treated with either buffer alone (to detect C4b bound to targets via ester
and amide linkages) or 1 M methylamine, pH 11 (to disrupt ester bonds), for 1 h
at 37°C, in a final reaction volume of 40 l. Direct determination of the specific
amide-bound C4b or C3b/iC3b is not possible, because it cannot be separated
intact from acceptor surfaces without altering its primary structure.
Gonococcal strains FA1090, MS11, 15253, and FA19 bind the complement
regulatory protein C4b-binding protein (C4BP) (51), which results in degrada-
tion of C4b bound to the organism. To minimize C4b cleavage, NHS was sup-
plemented with fAb104 (fAb fragment of anti-C4BP antibody 104), which blocks
C4BP binding to gonococci and inhibits the function of C4BP in solution, thus
preventing C4BP from serving as a cofactor in the factor I-mediated cleavage of
C4b to its C4c and C4d fragments (51). Blocking C4b degradation enables
identification of each C4b target linked to a single C4 fragment, thereby allowing
a more accurate estimate of the molecular masses of C4b target molecules. In
some experiments, we used the K-76 salt of monoacetic acid (K-76COONa; kind
gift of Guang Wang, Otsuka Pharmaceuticals, Rockville, MD) as a factor I
inhibitor (27, 28) to prevent the cleavage of C4b and C3b to C4d and iC3b,
respectively. Two volumes of a 4-mg/ml solution of K-76COONa (9.09 mM) in
phosphate-buffered saline (PBS) was mixed with 1 volume of serum (final con-
centration of K-76, 2.6 mg/ml) for 1 h on ice prior to use in Western blotting
experiments (26).
Samples were solubilized with lithium dodecyl sulfate sample buffer (NuPAGE
LDS sample buffer; Invitrogen) containing 2-mercaptoethanol (2.5% final con-
centration) at 37°C for 30 min. Proteins were separated on NuPAGE Novex 4 to
12% bis-Tris gradient gels using NuPAGE 3-morpholinopropanesulfonic acid
running buffer (Invitrogen) (40 mV for 15 h at 4°C). Western blotting was
performed as described previously (70). C4b was detected using anti-C4 at a
dilution of 1:1,000 in PBS containing 0.05% Tween 20 and disclosed as previously
described (49). Similarly, C3b and iC3b were detected using MAb 755 (1 g/ml)
and MAb G-3E (undiluted tissue culture supernatants containing 20 g/ml of
Ab), respectively. Gonococcal Por1B and Opa proteins were detected using
anti-Por1B MAb 5.51 (1 g/ml) and mouse anti-Opa MAb 4B12 (1:1,000 or 1
g/ml) diluted in PBS-Tween.
Relative molecular weights of C4b- and C3b-target complexes were calculated
based on a logarithmic curve fit of the migration of known standards. In all cases
the R2 value of the regression equation exceeded 0.97. Discrepancies between
observed and predicted molecular weights may be explained by incomplete
denaturation. In this system, the C4b- and C3b-target complexes remain co-
valently linked (i.e., they are not fully denatured) and thus their migration will be
affected by both the molecular mass and the conformation of the complex.
RESULTS
C4b targets on N. gonorrhoeae. Activation of the classical
pathway ultimately results in the 87-kDa C4b fragment of C4
being linked, via either an amide or ester bond, to a target
molecule on the bacterial cell surface. These C4b-target com-
plexes can be detected by Western blot analysis using anti-C4
Ab and their masses crudely estimated based on migration
velocities. The nature of the C4b-target bond can be inferred
from methylamine cleavage of ester bonds. We examined C4b
targets on five strains of N. gonorrhoeae (three representing
Por1A and two representing Por1B serotypes) following incu-
bation with 20% NHS. Four of these strains (FA1090, MS11,
15253, and FA19) bind the complement regulatory protein
C4BP (51), which serves as a cofactor in factor I-mediated
cleavage of C4b to its C4c and C4d fragments. We used fAb104
(51) to block C4BP binding and subsequent C4b degradation.
This resulted in each C4b target being linked to a single C4
fragment (C4b), thereby enabling a more accurate estima-
tion of the molecular masses of C4b-binding molecules.
Using these techniques, three gonococcal C4b-target com-
plexes with calculated masses of 88 kDa, 100 kDa, and 130
kDa were detected (Fig. 1). After accounting for the mass of
C4b (87 kDa), these data implicate gonococcal C4b targets
of approximately 1 kDa, 13 kDa, and 43 kDa. Of note, C4b-
target complexes likely exhibit anomalous migration in sodium
dodecyl sulfate-polyacrylamide gel electrophoresis, because
proteins migrate relative to their molecular mass only when
they are fully denatured. Following covalent attachment of C4b
to microbial targets, we intentionally avoided heating of the
samples to prevent complete denaturation of the complexes
and potential loss of epitopes needed for recognition by anti-
bodies in Western blot experiments; therefore, tertiary and
quaternary structure of these complexes may have impacted
migration and calculation of true molecular masses. None of
the anti-C4-reactive bands was seen in control samples lacking
NHS (data not shown; see the anti-C4 blots in Fig. 2 and 4,
below, as examples).
C4b formed complexes with a low-Mr (1-kDa) surface mol-
ecule in all strains tested (Fig. 1, C4bLOS). We demon-
strated previously that similar complexes in N. meningitidis
(which has a LOS structurally similar to N. gonorrhoeae) are
C4b-chain linked to phosphoethanolamine residues on LOS
via amide bonds or C4b-chain linked to hydroxyl groups on
LOS via ester bonds (49). The C4b-LOS bonds on strains F62,
FA19, and UU1 were predominantly methylamine resistant,
indicating amide-C4b-LOS bonds (Fig. 1). In contrast, the link-
ages on strains MS11 and 15253 were completely disrupted by
methylamine treatment, indicating the presence of only ester
linkages between C4b and LOS.
The two remaining gonococcal C4b targets have not been
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described previously. The 130-kDa C4b-target complex
was observed on strains F62 and MS11, whose porin molecules
are of the Por1B serovar, but the complex was absent on
Por1A strains FA19, UU1, and 15253. Porin, the most abun-
dant protein in the gonococcal outer membrane, has a pre-
dicted molecular mass of 35 kDa (Por1A) or 37 kDa
(Por1B) and forms trimers in the outer membrane. The fifth
exposed loop of Por1B is approximately 15 amino acids longer
than the corresponding loop in Por1A, hence, the smaller
molecular mass of Por1A. We hypothesized that C4b was
complexed with Por1B. In addition, all gonococcal strains, with
the exception of F62, showed a C4b-containing band that mi-
grated at approximately 100 kDa and appeared to be polymor-
phic (Fig. 1). None of the C4b-containing complexes at 100
kDa was affected by methylamine treatment, suggesting that
these molecules formed amide bonds with C4b.
Gonococcal Por1B is a target for C4b and iC3b. To deter-
mine if Por1B was indeed present in the 130-kDa species,
samples prepared from Por1B strain MS11 were evaluated in
parallel lanes of the same Western blot probed with either
anti-C4 Ab or anti-Por1B MAb (MAb 5.51). As seen in Fig. 2,
MAb 5.51-reactive bands migrated in parallel with anti-C4-
reactive bands at 130 kDa and 200 kDa, indicating that
Por1B was bound to C4b in these complexes. The higher-
molecular-weight (MW) band likely represents C4-containing
heterodimers (C5 convertases) assembled on Por1B. The
C4b-Por1B band was resistant to methylamine treatment,
indicating an amide linkage. The C5 convertases containing
amide-linked C4b-Por1B were reduced by methylamine
treatment, as expected, due to the presence of an internal ester
bond between C3b and C4b in these structures (69).
An approximately 110-kDa MAb 5.51-reactive band, which
did not migrate in parallel with any C4-reactive band, was also
noted (Fig. 2). This band was diminished in samples treated
with methylamine, suggesting it contained Por1B linked to
another serum component via an ester bond. C3 is the most
abundant complement protein in human serum. Activation of
C3 results in deposition of C3b (106 kDa) on bacterial surface
molecules, an important step that leads to the eradication of
microbes. Deposition of C3b, like C4b, occurs by reduction of
an internal thioester that results in an ester or amide bond with
the target. C3b prefers hydroxylated targets and is most often
found linked to targets by an ester bond. Much of C3b depos-
ited on Neisseria is converted to iC3b (68 kDa), which results
from cleavage of C3b by factor H (cofactor) and factor I
(enzyme) (16, 34, 44, 74), and we postulated that the 110-
kDa band could be iC3b ester linked to Por1B. Complexes of
iC3b with target molecules can be detected by Western blotting
using anti-iC3b Ab (MAb G-3E). As seen in Fig. 2, the 110-
kDa MAb 5.51-reactive band migrated in parallel with an
iC3b-reactive band, indicating that Por1B also bound C3b that
was subsequently converted to iC3b. Treatment with methyl-
amine released the ester-linked 1 (68-kDa) fragment of iC3b,
which appears as C3b1 in the methylamine-treated lane
probed with MAb G-3E (anti-iC3b). The released Por1B is not
visible because it has migrated off the gel.
The central region of Por1B contains the binding site for
C4b. Each porin polypeptide contains eight surface-exposed
loops. Although the primary amino acid sequences of the Por1A
and Por1B polypeptides are nearly identical in the membrane-
spanning regions, the sequences are variable in the surface-ex-
posed domains. To define the region in Por1B that acted as the
FIG. 1. C4b binding to five strains (two Por1B and three Por1A) of N. gonorrhoeae. Bacteria were incubated with NHS (final concentration,
20% [vol/vol]) containing fAb104, which blocked binding of C4BP to bacteria and prevented degradation of C4b. Western blots were probed with
polyclonal anti-human C4 and show C4-target complexes at 90 kDa, 100 kDa, and 130 kDa (the latter only on the two Por1B strains).
Higher-molecular-mass (200-kDa) complexes were also seen (indicated by the left bracket) and represent C4b-containing heterodimers (C5
convertases) linked to these bacterial targets. Methylamine treatment, which releases ester-bound, but not amide-linked, C4b  chains (87 kDa),
did not dissociate the 100-kDa and 130-kDa C4b-target complexes. The LOS-C4b complexes on strains F62, FA19, and UU1 (but not MS11
and 15253) were predominantly methylamine resistant. The position of the C4  chain in the lane marked NHS is indicated by  (95).
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binding site for C4b, we assessed C4b deposition in gonococcal
Por1A/B hybrid strains that were created with strains FA19
(Por1A) and MS11 (Por1B). As seen in Fig. 3, only strains that
bore a Por molecule containing Por1B loops 4 and 5 bound C4b.
These data suggest that the primary binding site for C4b on
Por1B is a region spanned by Por1B loops 4 and 5 and that
sequence variation in the exposed portions of these loops in the
Por1A molecule may abrogate binding of C4b.
FIG. 2. Por1B binds C4b and iC3b. Strain MS11 (Por1B) was incubated with NHS treated with fAb104, and samples were processed for
Western blotting as described in the legend for Fig. 1. Organisms incubated with only HBSS2 (Org alone) were used as negative controls. Parallel
samples transferred to the same membrane were incubated with anti-C4, anti-Por1B MAb 5.51, or anti-iC3b MAb G3-E. Arrowheads indicate
bands that migrated in parallel and reacted with both the anti-Por1B MAb 5.51 and the anti-C4 antibody. Similarly, asterisks indicate bands that
migrated in parallel and reacted with both the anti-Por1B MAb 5.51 and the anti-iC3b antibody. The location of the 95-kDa C4  chain [ (95)]
and the 68-kDa iC3b 1 chain [iC3b1(68)] are indicated in the lanes containing NHS alone and pure iC3b, respectively.
FIG. 3. C4b binds to Por1B within the region spanned by loops 4 and 5. C4b binding to strains that express hybrid Por1A/1B molecules (derived from
Por1A strain FA19 and Por1B strain MS11) was examined following incubation with NHS and fAb104 as described in the legend for Fig. 1. A schematic
representing the Por molecule of each hybrid strain and their ability to bind to C4b are shown beneath the blots. The hybrid class designation is as
described by Carbonetti et al. (10). Por1A (FA19) sequence is indicated by the hatched line, and the Por1B (MS11) sequence is indicated by the solid
black line. C4b-Por complexes were seen only in strains that possess Por1B loops 4 and 5 (indicated by a shaded gray box in the schematic).
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Opa is a target for C4b and C3b. The neisserial opacity
proteins (Opa) are a polymorphic family of phase-variable
outer membrane proteins with molecular masses of approxi-
mately 28 kDa that are associated with colony opacity. Gono-
cocci may carry as many as 11 distinct opa genes (opaA to
opaK) that are independently switched on and off at a fre-
quency of 102 to 103 per cell generation. Based on the allelic
variation of the 100-kDa C4b-target complex, we hypothesized
that this C4b target was Opa. To test this hypothesis, we ana-
lyzed C4b deposition on variants of FA1090 that expressed
predominantly a particular Opa (Opa A, B, C, D, E, F, or I) or
no Opa at all. fAb104 was used to block C4BP activity on the
bacterial surface. Parallel Western blots were probed with the
anti-C4 Ab and anti-Opa MAb 4B12. Representative binding
of C4b to the FA1090 Opa variants is shown in Fig. 4. The
polymorphic 100-kDa complex was seen on all Opa-expressing
strains and was recognized by both anti-C4 and anti-Opa Abs
(Fig. 4). The size variations seen in the Opa-C4b complexes
with the anti-C4 antibody are also mirrored with the anti-Opa
antibody. In further support of Opa as a C4b target, the Opa-
negative mutant did not show a complex that reacted with
either Ab at this location (Fig. 4). All Opa-C4b complexes were
resistant to methylamine treatment, suggesting that C4b
formed amide bonds with Opa (Fig. 4). Together, these data
corroborate C4b-Opa interactions on strain FA1090. As seen
above with Por1B interactions with C4b and iC3b, anti-C4 and
anti-Opa coreactive bands were also seen at 200 kDa; these
likely represent C4-containing heterodimers (C5 convertases)
bound to Opa and were dissociated by methylamine.
An Opa-containing fragment with an apparent molecular
mass of 140 kDa was also evident (Fig. 4). This band did not
migrate in parallel with any C4-reactive band and was dimin-
FIG. 4. Gonococcal Opa binds to C4b. (A and B) FA1090 derivatives that express predominantly an individual Opa protein (OpaA, -B, -C, -D,
-E, -F, or -I), FA1090 that expresses OpaB, and an FA1090 Opa-negative mutant were incubated with NHS containing fAb104 (blocks C4BP
binding to gonococci) and processed with (B) or without (A) methylamine as described in the legend for Fig. 1. Control lanes contained NHS and
OpaA-expressing FA1090 and were processed as above but not treated with serum (Orgs. alone). Parallel samples, on the same blot, were probed
with either anti-C4 or anti-Opa monoclonal Ab 4B12. Anti-C4- and anti-Opa-reactive bands that migrated at the same velocity are indicated as
OpaC4b and marked with asterisks to the right of the bands. C4-Opa complexes were methylamine resistant (asterisks), suggesting amide
linkages. The control Opa-negative mutant does not show C4-Opa complexes at 100 kDa. The faint 140-kDa Opa-reactive band (marked by a
diamond in the top right blot that is absent in the Opa-negative mutant and in organisms not treated with serum), which does not localize with
any band in the corresponding anti-C4 blot and that also becomes less intense with methylamine treatment, represents C3b bound to Opa (see Fig.
5, below). The location of the 95-kDa C4  chain is indicated in each NHS lane as  (95). The relative molecular weights of the molecular weight
standards are indicated. The C4b  (87 kDa) released from C5 convertases and ester-linked targets is indicated on the blots treated with
methylamine. (C) Specificity of MAb 4B12 for Opa proteins in whole-cell lysates. The position of the Opa protein in each strain is noted by an
arrow. A 96-kDa neisserial protein marked with an x also reacts with MAb 4B12. This protein is also present in the Opa-negative mutant and
in samples incubated with or without serum. Porin-C4b and LOS-C4b complexes are marked with a P and L, respectively.
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ished in samples treated with methylamine, suggesting it con-
tained Opa linked to a serum component via an ester bond.
Although we did not block factor I activity, the apparent mo-
lecular mass of this complex suggested that it could represent
residual C3b (106 kDa) linked to Opa (28 kDa).
Although prior work has shown that most of the C3b depos-
ited on Neisseria is converted over 30 to 60 min to iC3b (16, 34,
44, 74), we postulated that C3b bound to certain bacterial
targets may be resistant to cleavage to iC3b. C3b-Opa com-
plexes with a predicted molecular mass of134 kDa would not
have been detected by the anti-iC3b MAb (G-3E) that we have
used thus far. To address this possibility, we blocked C3b
conversion to iC3b using the factor I inhibitor K-76COONa
and detected C3b using MAb 755. Confirmation of a C3b-Opa
complex is provided in Fig. 5. Data with wild-type strain
FA1090, its Opa A and Opa B variants, and the Opa-
negative control are shown. Parallel migration of the 140-
kDa target with anti-Opa and anti-C3 MAb 755 is indicated in
Fig. 5 as C3bOpa. The Opa-negative mutant lacks a
C3b-containing complex at this location. The additional
C3b-containing complexes seen migrating at 150 kDa and
110 kDa represent the C3b chain (106 kDa) bound to
Por1B (37 kDa) and LOS (4 kDa) targets. Methylamine
treatment (right blot) resulted in release of almost all C3b
bound to bacterial targets and the appearance of the released
106-kDa C3b chain. The methylamine-resistant Opa-con-
taining bands around 105 kDa seen on the Opa-expressing
strains represent C4b bound to Opa as described above.
Binding of isoforms of C4 to gonococci. Two isoforms of C4,
called C4A and C4B, which differ in their biological properties,
are found in normal human serum. C4A forms amide linkages
with its targets, while C4B forms mainly ester linkages. We
used sera that contained only C4A or C4B to determine how
each of these isoforms of C4 binds to gonococci. FA1090
OpaB and the Opa-negative mutant were used to illustrate
these differences. As seen in Fig. 6, serum that contained only
C4A showed monomers of C4Ab bound to LOS, Opa, and
Por1B on the OpaB strain. In addition, heterodimers assem-
bled on these three distinct targets were apparent. In contrast,
with serum containing only C4B, bands representing mono-
meric C4Bb on these targets were very faint; however, the
C4Bb-containing C5 convertases were readily visualized, high-
lighting the propensity for C4Bb to preferentially form C5
convertases. Methylamine treatment of these C4Bb-containing
convertases resulted in release of free C4Bb but not in the
appearance of amide-linked targets. This suggests that C4Bb
was ester linked to LOS, Opa, and Por1B in these complexes.
When both isoforms were present, a pattern that was interme-
diate and representative of both C4 isoforms was seen. Similar
results were seen with the Opa-negative mutant, except that
the Opa-C4 monomers as well as the heterodimers assembled
on Opa (seen on the Opa-positive strain) were absent.
Methylamine treatment confirmed the amide nature of the
C4Ab-target complexes. Intensification of C4b target(s) with
methylamine treatment compared to non-methylamine-treated
specimens, best seen in lanes 2 and 5 of the methylamine-
treated samples (right blot), resulted from release of the C3
fragment that is ester linked to the C5 convertase, which also
contained C4b-target complexes. The released C4b target(s)
then migrated together with preexisting monomeric C4Ab-
target complexes, thereby resulting in an increased intensity of
the C4Ab-target adduct. A faint band corresponding to re-
leased 87-kDa -chain was seen (in lanes 2 and 5 of the right
blot, for example), suggesting a predominance of amide link-
ages. In contrast, bacteria incubated with C4B-containing se-
rum showed a prominent released 87-kDa  chain upon meth-
ylamine treatment, also confirming the presence of ester
linkages between C4Bb and bacterial targets.
C4 binding sites on meningococci. We previously described
LOS as a target for C4b on meningococci (49). Our studies
presented above have indicated that in gonococci LOS, Opa,
and Por1B are all targets for C4b. Meningococci express Opa
FIG. 5. Opa binds C3b via ester linkages. Samples were incubated with NHS containing fAb104 and K-76COONa (the monoacetic salt of K-76,
which inhibits factor I activity), with anti-C3 MAb 755, and polyclonal anti-Opa antibody. Shown are representative data with the OpaA, OpaB,
and Opa-negative derivatives of strain FA1090. Opa-C3b complexes are indicated by the arrow labeled C3b  Opa. The susceptibility of the
linkage to methylamine indicates an ester C3b-Opa linkage. The position of the -chain of C3 (115 kDa) in the NHS lane is indicated as C3; the
released C3b  chain (106 kDa) in methylamine-treated samples probed with MAb 755 is indicated as C3b . The location of the Opa-C4b
complexes (shown above in Fig. 4) at 105 kDa is indicated by an asterisk.
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and Por proteins that are similar to the gonococcal counter-
parts and, thus, we wished to further examine C4b targets in
meningococci. We examined C4 binding sites on two sero-
group B meningococcal strains, MC58 and H44/76, and their
unencapsulated mutants that lack LOS sialic acid (siaD lst
mutants). Because capsular polysaccharide and LOS sialic acid
regulate complement (55, 73), the wild-type strains were
incubated with 50% NHS, while the siaD lst mutants were
incubated with 10% NHS. We did not use fAb104 in these
experiments, because binding of C4BP to meningococci in
physiologic buffers is very weak (33) and preliminary experi-
ments showed that the majority of C4b bound to meningococci
remained unprocessed. As seen in Fig. 7A, the targets for C4b
were similar on the wild-type strains and the siaD lst mutants,
suggesting that neither serogroup B capsular polysaccharide
nor LOS sialic acid altered the site of C4b binding when bac-
teria were incubated with NHS. Two C4b-containing com-
plexes were seen with MC58. One, migrating at approximately
91 kDa, is the previously identified complex containing C4b
and LOS (49), and the other, akin to the observations above
with gonococci, was a complex that migrated at105 kDa. The
105-kDa complex was fainter on H44/76, while the LOS-C4b
band appeared more intense. Methylamine treatment did not
release the 20-kDa target from C4b but did disrupt the LOS-
C4b linkage on MC58. Methylamine-resistant C4b-LOS com-
plexes were seen on H44/76 and its siaD lst mutant (Fig. 7A),
suggesting the presence of amide linkages between the two mol-
ecules. Phosphoethanolamine residues have been shown to me-
diate amide linkages of C4b to LOS. Two C4-reactive bands are
also present at200 kDa (Fig. 7A), and these likely represent C5
convertases assembled on LOS and the 20-kDa target.
We hypothesized that the 20-kDa target was Opa and that
strain MC58 expressed more Opa than strain H44/76, account-
ing for greater intensity of this complex. Consistent with this
hypothesis, Western blot assays of whole-cell lysates of MC58
and H44/76 with anti-Opa MAb 4B12 confirmed greater Opa
expression on MC58 (Fig. 7B). Coomassie blue staining of
outer membrane preparations validated equal sample loading
and corroborated Western blot analysis results (data not
shown). Parallel migration of the 105-kDa anti-C4-reactive
band with the anti-Opa MAb bands confirmed the presence of
Opa as a target for C4b on MC58 (Fig. 7C). Band intensity was
not affected by methylamine treatment, indicating amide link-
ages between Opa and C4b. In a separate experiment, the
prominent 90-kDa anti-Opa-reactive band (Fig. 7C) that de-
creased in intensity with methylamine treatment was shown to
be Opa bound to the 68-kDa iC3b1 chain (data not shown).
As additional evidence for Opa-C4b interactions in N. meningiti-
dis, we analyzed C4b deposition in serogroup A strain Z2087 and
its isogenic mutant that lacks Opa expression. As seen in Fig. 7D,
Opa deletion resulted in a corresponding loss of the 105-kDa
complex. MC58 siaD lst was included as a positive control. Col-
lectively, these data provide strong evidence that meningococcal
Opa also binds C4b via amide linkages.
MC58 and H44/76 both express PorB3 molecules which bear
sequence homology to gonococcal Por1A. We observed no
C4b-containing complexes at molecular masses that would im-
plicate this meningococcal porin as a C4b target. Previously
published data using meningococcal strain Y2220, which ex-
presses a PorB2 molecule (the meningococcal equivalent of
gonococcal Por1B) (49), in addition to our unpublished data
from using two other PorB2-expressing strains called C2120
FIG. 6. Binding of C4 isoforms to N. gonorrhoeae. Sera containing only the C4A isoform (preferentially forms amide linkages) or only the C4B
isoform (preferentially forms ester linkages) were incubated with OpaB and Opa variants of strain FA1090, and the nature of the C4b linkage
to targets was determined by Western blotting as described in the legend for Fig. 1. fAb104 was added to sera to minimize binding of C4BP and
diminish C4b degradation to C4d. C4A bound to LOS, Opa, and Por; no release of C4b -chain was seen with methylamine treatment, indicating
that C4Ab bound to these three targets via amide linkages. Note that the binding of C4Ab to Por and Opa appears as “doublets.” In contrast, C4Bb
bound to targets was detected predominantly as part of high-MW C5 convertases assembled via the three major targets; a minimal amount of
“monomeric” C4Bb bound to targets. Bound C4Bb was completely released by methylamine, suggesting internal ester linkages within the
convertases. Incubation of strain FA1090 with NHS and fAb104 (indicated as lanes containing both C4A and C4B) showed a pattern that was
intermediate or representative of both the C4A- and C4B-only containing sera.
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and W171, showed no evidence of PorB2-C4b interactions
(data not shown). Based on these observations, it appears that
meningococcal porins, in contrast to gonococcal Por 1B porins,
are not targets for C4b deposition.
DISCUSSION
The complement system recognizes invading pathogens,
such as pathogenic Neisseria, and facilitates killing directly or
by enhancing opsonophagocytosis using a process of targeted
complement activation on the microbial surface. Two comple-
ment molecules that play a key role in activation are C4 and
C3. Both of these molecules possess internal thioester bonds
which, when activated, are highly labile and can bind to prox-
imate hydroxyl or amide groups that serve as electron donors
(14, 29). While activation of complement on a microbial sur-
face may be beneficial in combating infection, unimpeded ac-
tivation can cause excessive inflammation and result in detri-
mental effects on host tissues. Therefore, activation of the
complement system is tightly controlled by several fluid-phase
and membrane-bound regulatory molecules (reviewed in ref-
erence 75). The intrinsic nature of a complement binding sur-
face plays an important role in determining whether activation
will be favored over regulation. For example, factor H (inhib-
FIG. 7. C4b targets on N. meningitidis. Wild-type strains MC58 and H44/76 (encapsulated and LOS sialylated) and their siaD lst derivative
mutants (unencapsulated; LOS not sialylated) were incubated with NHS (final concentration, 50% [vol/vol]) for wild-type strains and 10% [vol/vol]
for siaD lst mutants); C4b targets were determined as described in the legend for Fig. 1. (A) C4b bound to a low-MW target (complex at 90 kDa)
on both strains, which has been identified previously as LOS (49). Methylamine-resistant C4b-LOS complexes seen in H44/76 are marked with an
asterisk. A second complex at 105 kDa (shown to be Opa in panel C) was more prominent on MC58. C5 convertases assembled via these two
targets were seen at 200 kDa (marked by the arrowhead). Both the 105-kDa C4b -chain-containing complex and the LOS-C4b  complex on
H44/76 resisted methylamine treatment, indicating the presence of amide linkages. (B) Opa expression on MC58 and H44/76. Western blots of
bacterial lysates (normalized in amounts electrophoresed and transferred) were probed with anti-Opa MAb 4B12; strain MC58 shows greater Opa
expression. (C) The 105-kDa C4b-target complex on MC58 siaD lst contains Opa. MC58 siaD lst was incubated with NHS, and samples were
processed as described previously. Samples run in parallel were probed with either anti-C4 or with anti-Opa MAb 4B12. The half of the blot probed
with anti-Opa MAb 4B12 revealed an Opa-containing band that migrated in parallel with the 105-kDa C4b -containing complex. This band
resisted methylamine treatment, indicating an amide linkage. The asterisk indicates a methylamine-sensitive band containing Opa bound to the
68-kDa iC3b1 chain (data not shown). (D) Deleting Opa results in loss of the 105-kDa C4b -containing complex. Strain Z2087 and its
Opa-negative isogenic mutant were examined for C4b binding as described above. Strain MC58 siaD lst was used as a positive control. The
Opa-negative mutant of Z2087 did not show a 105-kDa adduct, confirming Opa as a target for C4b.
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itor) has a greater affinity than factor B (activator) for C3b on
normal sheep erythrocytes, rendering this surface a nonactiva-
tor of complement; desialylation results in enhanced affinity of
factor B for C3b and results in complement activation (18, 36).
Activation of the complement system can result in rapid
death of an invading organism and, therefore, it is not surpris-
ing that microbes, particularly uniquely human pathogens like
neisseriae, have evolved a broad array of strategies to limit
activation of human complement on their surfaces (59). Cap-
sular polysaccharides may limit C3 binding to bacteria or may
shift C3 deposition to less-effective sites on the bacterial mem-
brane (45), thereby limiting membrane attack complex inser-
tion. Another mechanism to evade complement activation is to
bind complement regulatory proteins such as factor H and
C4BP (reviewed in reference 38). Evasion of complement is
critical for neisseriae to colonize humans and cause disease,
and these bacteria employ several, often redundant, mecha-
nisms to escape killing by complement. Both N. gonorrhoeae
and N. meningitidis bind factor H and C4BP, which results in
complement regulation and enhanced serum resistance (33, 39,
48, 50–53, 55). In addition, the ability to modulate binding of
C4b and C3b may further impact the net amount of comple-
ment that can be activated.
Neisserial LOS has previously been identified as a target for
both C3b and C4b (15, 49). In this study we have established
that two additional membrane structures, gonococcal Por1B
and Opa, also serve as ligands for C3 and C4 binding. These
targets were detected using multiple serum pools, and immu-
noblotting was used to demonstrate that the NHS was not
biased to anti-Por, anti-Opa, or anti-LOS antibodies (data not
shown). Por1A-bearing gonococci have been associated with a
serum-resistant phenotype that persists after subpassage and
an ability to cause disseminated disease, while gonococcal
strains expressing Por1B usually are serum sensitive after pas-
sage (unsialylated) and more commonly cause a local genital
infection (8, 23, 58). The difference in serum resistance be-
tween Por1A and Por1B isolates results from preferential
binding of factor H and C4BP to Por1A strains (51, 54). In this
study we have described preferential binding of C4b and C3b
to Por1B. This may contribute further to the enhanced serum
sensitivity of Por1B strains relative to their Por1A counter-
parts. The site of C4b binding was localized to the region
spanned by loops 4 and 5 of Por1B. Loop 5 in Por 1B of N.
gonorrhoeae may contain the binding site(s) for C4b because of
the presence of unique sequences that either diverge or are
absent in the corresponding regions of Por1A (13, 24); the
predicted surface-exposed region of loop 5 of Por1A contains
only 9 amino acids, while the corresponding region of Por1B
has 25 amino acids. Binding of C4b was restricted to gono-
coccal Por1B and was not observed in the meningococcal ho-
mologue of gonococcal Por1B, PorB2. The amino acid se-
quence of the fifth loop of the meningococcal PorB2 is not
conserved with the gonococcal Por1B loop 5 sequence (12%
identity).
The interaction of complement C3 with porin molecules has
been described in other organisms. The facultative intracellu-
lar pathogen Legionella pneumophila uses surface-bound C3
fragments to gain entry into mononuclear cells via CR1- and
CR3-mediated phagocytosis. The major outer membrane pro-
tein, a porin molecule, is the only C3-fixing molecule that has
been found on the surface of L. pneumophila (2). Further,
Alberti et al. have shown that porins are the most important
site of C3b deposition in serum-sensitive strains of Klebsiella
pneumoniae and have further proposed that differences in the
amount of C3b bound dictate serum sensitivity versus serum
resistance. In serum-resistant K. pneumoniae, C3b binding to
porin is inhibited by smooth lipopolysaccharide and total C3b
deposition is lower than on serum-sensitive strains (1).
We also found that Opa proteins bound C4b and C3b. Opa
proteins play a key role in mediating adhesion and invasion of
bacteria into epithelial cells (10, 11, 40). An earlier report
indicated that gonococcal colonies identified in women around
menses (when menstrual blood contributes to a higher level of
complement locally) and examined after a single agar subpas-
sage are mostly of the transparent phenotype (i.e., more likely
to be Opa negative), while colonies identified at other times in
the cycle tend to be opaque (68). Women are uniquely suscep-
tible to disseminated gonococcal infection during menses (57),
and serum-resistant strains isolated from blood are also more
likely to produce transparent colonies (43). Similarly, menin-
gococci recovered from the blood or cerebrospinal fluid com-
monly grow as transparent colonies, while those recovered
from the nasopharynges of asymptomatic carriers are usually
opaque (67). Thus, it appears that neisseria that encounter
high levels of complement (as occurs during menses or during
bloodstream infection) tend to turn Opa expression “off.” It is
possible that loss of a target for C4b and C3b may confer an
advantage in combating complement.
A prior report by Bos et al. (7) indicated that Opa expression
by gonococcal strain MS11 enhances serum resistance. We
were unable to detect differences in serum resistance between
FA1090 and its Opa variants that were used in this study. All
the strains were resistant (50% survival) to even 40% NHS;
FA1090 is resistant to serum by virtue of its ability to bind
C4BP (51). In contrast, the MS11 variant used by Bos et al. (7)
was sensitive to serum. LOS analysis by silver staining of so-
dium dodecyl sulfate-polyacrylamide gel electrophoresis gels
showed that FA1090 and each of its Opa mutants expressed
more than one LOS species and that there was wide variation
in LOS expression among the strains (data not shown). LOS
structure also impacts complement binding and serum resis-
tance (20, 21, 49, 65, 66), and therefore it was not possible to
assess the effects of Opa expression on complement-dependent
killing independent of other potential serum resistance-modi-
fying variables on the strains we used. It is possible that Opa
expression may have different effects on serum resistance in
different strains, and LOS-Opa interactions may also play a
role in modulating the effects of Opa (4, 47).
Human C4 is subject to great genetic diversity stemming
from a complex pattern of genetic differences in gene size,
gene number, and nucleotide polymorphisms (12, 80). In hu-
mans, deficiency in some aspect of C4 expression, often with-
out consequences, such as increased susceptibility to infec-
tions, represents the most common form of complement
deficiency (6). Individuals generally have between two and
eight C4 genes (diploid chromosome), with each locus encod-
ing either a C4A or C4B molecule (5, 79). In addition more
than 41 C4 variants can be detected by differences in electro-
phoretic mobility (42). Partial C4 isoform deficiencies are rel-
atively common, with the prevalence of complete C4A or C4B
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deficiencies being reported at a combined frequency of 2% (6,
22). Functionally, C4A and C4B are defined by variance of four
critical amino acids located at residues 1101 to 1106. These
differences endow C4A with an ability to react with amino
group-containing antigens, a longer half-life, and an important
role in immune clearance and opsonization. C4B preferentially
forms ester bonds with hydroxylated targets, has a short half-
life, and is important in accelerating classical pathway activa-
tion and membrane attack complex formation (14, 32, 56, 62).
C4A deficiency has been associated with susceptibility to au-
toimmune diseases, while C4B deficiency may be more associ-
ated with vulnerability to bacterial and viral infections (3, 6, 61,
71). Differential complement activation, resulting from partial
or complete C4 deficiency, may impact the susceptibility of a
person to disease. For example, an individual that possesses
only the C4B isoform (forms predominantly ester linkages)
may have an impaired ability to activate complement on a
surface where there are relatively limited numbers of available
hydroxyl groups that can act as electron donors. Similarly, if
available targets on the bacterial surface dictate the nature of
the C4-target linkages, and therefore the isoform of C4 that
binds to the bacterium, then these targets may impact the
immune response. It is noteworthy that LOS and Opa are
phase variable, which could allow the bacteria to further mod-
ulate complement activation.
A closer examination of the Por1B-C4b complex reveals a
double band in several instances. The slower-migrating band is
more prominent in strain MS11 (Fig. 1, 2, and 3), while both
bands are of similar intensity in strain FA1090 (Fig. 4 and 6).
The smaller of the two C4b-Por1B complexes in serum-sensi-
tive MS11 appears to be sensitive to methylamine and thus may
be C4Bb, which preferentially forms ester bonds, linked to
Por1B. C4Bb-containing complexes are a component of the
active C5 convertase, which is more likely to lead to the for-
mation of membrane attack complexes (14, 32, 56, 62). In
contrast, both of the C4b-Por1B complexes in serum-resistant
strain FA1090 (which also binds the complement regulatory
protein C4b-binding protein) resist methylamine treatment
and thus may be C4Ab complexes, which are less likely to form
membrane attack complexes.
We did not detect C4b or C3b binding to other more con-
served and constitutively expressed membrane molecules, such
as Rmp or lipoprotein H.8 (data not shown).
In summary, we have defined neisserial Opa and gonococcal
Por1B, in addition to LOS, as targets of binding for comple-
ment components C4b and C3b. The ability of pathogenic
Neisseria to infect humans depends on effective evasion of
complement; resistance to complement-mediated killing is de-
termined in part by the qualitative aspects of complement
deposition and activation. A better understanding of neisserial
structures that are targets for complement deposition and their
role in complement resistance will enhance our understanding
of susceptibility to neisserial disease and may contribute to
rational vaccine design.
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